Comparison between anatomical cross-sectional imaging and 18F-FDG PET/CT in the staging, restaging, treatment response, and long-term surveillance of squamous cell head and neck cancer: A systematic literature overview

Nuclear Medicine Communications

Volumn 35, Issue 2, 2014, Pages 123-134

  Evangelista, Laura ^a   Cervino, Anna Rita ^a   Chondrogiannis, Sotirios ^b   Marzola, Maria Cristina ^b   Maffione, Anna Margherita ^b   Colletti, Patrick M ^c   Muzzio, Pier Carlo ^a   Rubello, Domenico ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c University of Los Angeles   (United States)

Author keywords

18F FDG PET CT; contrast enhanced computed tomography; head and neck squamous cell cancer; imaging effectiveness; MRI; outcome; PET ceCT; response to treatment; restaging; staging

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADJUVANT CHEMORADIOTHERAPY; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER STAGING; CERVICAL LYMPH NODE; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LYMPH NODE METASTASIS; MANDIBLE CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIMARY TUMOR; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR INVASION;

CARCINOMA, SQUAMOUS CELL; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84891561361     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000022     Document Type: Review

References (59)

1. Goshen E, Davidson T, Yahalom R, Talmi YP, Zvas ST. PET/CT in the evaluation of patients with squamous cell cancer of the head and neck. Int J Oral Maxillofac Surg 2006; 35:332-336.
2. Medina J. Neck dissection. In: Bailey BJ, Johnson JT, Newlands SO, editors. Head and neck surgery otolaryngology. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. pp. 1586-1607.
3. Ducic Y, Young L, Mclntyre J. Neck dissection: past and present. Minerva Chir 2010; 65:45-58.
4. Jackel MC, Ambrosch P, Christiansen H, Martin A, Steiner W. Value of postoperative radiotherapy in patients with pathological N1 neck disease. Head Neck 2008; 30:875-882.
5. Kao J, Lavaf A, Teng MS, Huang D, Genden EM. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys 2008; 71:362-370.
6. De Bree R, Deurloo EE, Snow GB, Leemans CR. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 2000; 110:397-401.
7. Dennington ML, Carter DR, Meyers AD. Distant metastases in head and neck epidermoid carcinoma. Laryngoscope 1980; 90:196-201.
8. Black RJ, Gluckman JL, Shumrick DA. Screening for distant metastases in head and neck cancer patients. Aust N Z J Surg 1984; 54:527-530.
9. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
10. Brinkmann G, Brix F, Beigel A. Ultrasound, computerized and nuclear magnetic resonance tomography of soft tissue processes of the head and neck. Rontgenblatter 1990; 43:58-64.
11. Van den Brekel MW, Casteljins JA, Stel HV, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastases: assessment of radiologic criteria. Radiology 1990; 180:457-461.
12. 18F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 93:202-207.
13. Goerres GW, Schmid DT, Gratz KW, von Schulthess GK, Eyrich GK. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 2003; 39:547-551.
14. 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck 2004; 26: 890-896.
15. Goerres GW, Schmid DT, Bandhauer F, Huguenin PU, von Schulthess GK, Schmid S, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130:105-109.
16. Goshen E, Yahalom R, Talmi YP, Rotenberg G, Oksman Y, Zwas ST. The role of gamma-PET in the evaluation of patients with recurrent squamous cell cancer of the head and neck. Int J Oral Maxillofac Surg 2005; 34:386-390.
17. Schwartz DL, Rajendran J, Yueh B, Coltrera MD, Leblanc M, Eary J, et al. FDG-PET prediction of head and neck squamous cell cancer outcomes. Arch Otolaryngol Head Neck Surg 2004; 130:1361-1367.
18. Agarwal V, Branstetter BF IV, Johnson JT. Indications for PET/CT in the head and neck. Otolaryngol Clin North Am 2008; 41:23-49.
19. Gregoire V, Lefebvre JL, Licitra L, Felip E, EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21:v184-v186.
20. 18F)-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117:1173-1179.
21. Liauw SL, Mancuso AA, Amdur RJ, Hall CN, Daly BT, Agrawal A, et al. Postradiotherapy neck dissection for lymph node-positive head and neck cancer: the use of computed tomography to manage the neck. J Clin Oncol 2006; 24:1421-1427.
22. Porceddu SV, Jarmolowski E, Hicks RJ, Ware R, Weih L, Rischin D, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005; 27:175-181.
23. 18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report. Int J Radiat Oncol Biol Phys 2009; 74:9-14.
24. Lango MN, Myers JN, Garden AS. Controversies in surgical management of the node-positive neck after chemoradiation. Semin Radiat Oncol 2009; 19:24-28.
25. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008; 33:210-222.
26. Braams JW, Pruim J, Kole AC, Nikkels PG, Vaalburg W, Vermey A, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997; 26:112-115.
27. Laubenbacher C, Saumweber D, Wagner-Manslau C, Kau RJ, Herz M, Avril N, et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995; 36:1747-1757.
28. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998; 25:1255-1260.
29. Stuckensen T, Kovács AF, Adams S, Baum RP. Staging of the neck in patients with oral cavity squamous cell carcinomas: a prospective comparison of PET, ultrasound, CTand MRI. J Craniomaxillofac Surg 2000; 28:319-324.
30. 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003; 44:198-206.
31. Goerres GW, Schuknecht B, Schmid DT, Stoeckli SJ, Hany TF. Positron emission tomography/computed tomography for staging and restaging of head and neck cancer: comparison with positron emission tomography read together with contrast-enhanced computed tomography. Clin Imaging 2008; 32:431-437.
32. Andrade RS, Heron DE, Degirmenci B, Filho PA, Branstetter BF, Seethala RR, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 2006; 65:1315-1322.
33. Rodrigues RS, Bozza FA, Christian PE, Koffman JM, Butterfield RI, Christensen CR, et al. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med 2009; 50:1205-1213.
34. Ng SH, Chan SC, Liao CT, Chang JT, Ko SF, Wang HM, et al. Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology 2008; 50:969-979.
35. 18F-Fluorodeoxyglucose-PET/CT to evaluate tumor, nodal disease, and gross tumor volume of oropharyngeal and oral cavity cancer: comparison with MR imaging and validation with surgical specimen. Neuroradiology 2009; 51:677-686.
36. 18F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Eur Radiol 2009; 19:634-642.
37. 18F-FDG PET/CT and MRI in the follow-up of head and neck squamous cell carcinoma. Contrast Media Mol Imaging 2011; 6:260-266.
38. Gu DH, Yoon DY, Park CH, Chang SK, Lim KJ, Seo YL. CT, MR, (18)F-FDG PET/CT, and their combined use for the assessment of mandibular invasion by squamous cell carcinomas of the oral cavity. Acta Radiol 2010; 51:1111-1119.
39. 18F-FDG PET/CT and 3.0-T whole-body MRI for the detection of distant metastases and second primary tumours in patients with untreated oropharyngeal/hypopharyngeal carcinoma: a comparative study. Eur J Nucl Med Mol Imaging 2011; 38:1607-1619.
40. Ng SH, Chan SC, Yen TC, Liao CT, Lin CY, Tung-Chieh Chang J, et al. PET/CT and 3-T whole-body MRI in the detection of malignancy in treated oropharyngeal and hypopharyngeal carcinoma. Eur J Nucl Med Mol Imaging 2011; 38:996-1008.
41. 18F-FDG-PET/CT for the assessment of necrotic lymph node metastases. Head Neck 2011; 33:324-329.
42. Stoeckli SJ, Haerle SK, Strobel K, Haile SR, Hany TF, Schuknecht B. Initial staging of the neck in head and neck squamous cell carcinoma: a comparison of CT, PET/CT, and ultrasound-guided fine-needle aspiration cytology. Head Neck 2012; 34:469-476.
43. Fakhry N, Michel J, Colavolpe C, Varoquaux A, Dessi P, Giovanni A. Screening for distant metastases before salvage surgery in patients with recurrent head and neck squamous cell carcinoma: a retrospective case series comparing thoraco-abdominal CT, positron emission tomography and abdominal ultrasound. Clin Otolaryngol 2012; 37:197-206.
44. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cell? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 1993; 34:414-419.
45. Haberkorn U, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, et al. Glucose uptake, perfusion and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991; 32:1548-1555.
46. O'Brien CJ, Carter RL, Soo KC, Barr LC, Hamlyn PJ, Shaw HJ. Invasion of the mandible by squamous carcinomas of the oral cavity and oropharynx. Head Neck Surg 1986; 8:247-256.
47. Van den Brekel MW, Runne RW, Smeele LE, Tiwari RM, Snow GB, Castelijns JA. Assessment of tumour invasion into the mandible: the value of different imaging techniques. Eur Radiol 1998; 8:1552-1557.
48. Chung TS, Yousem DM, Seigerman HM. MR of mandibular invasion in patients with oral and oropharyngeal malignant neoplasms. Am J Neuroradiol 1994; 15:1949-1955.
49. Bolzoni A, Cappiello J, Piazza C, Peretti G, Maroldi R, Farina D, et al. Diagnostic accuracy of magnetic resonance imaging in the assessment of mandibular involvement in oral-oropharyngeal squamous cell carcinoma: a prospective study. Arch Otolaryngol Head Neck Surg 2004; 130: 837-843.
50. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med 2007; 357:2277-2284.
51. Jaffe TA, Yoshizumi TT, Toncheva G, Anderson-Evans C, Lowry C, Miller CM, et al. Radiation dose for body CT protocols: variability of scanners at one institution. AJR Am J Roentgenol 2009; 193:1141-1147.
52. 18F-FDG. Radiat Prot Dosim 2010; 139: 208-213.
53. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 2010; 51:866-874.
54. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007; 48:726-735.
55. 18F-FAZA). Eur J Nucl Med Mol Imaging 2009; 36:1565-1573.
56. 18F]EF3 in patients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging 2008; 35:1282-1289.
57. Yamane T, Kikuchi M, Shinohara S, Senda M. Reduction of [(18)F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol 2011; 13:227-231.
58. 18F-FDG PET/CT. Mol Imaging Biol 2011; 13:1036-1042.
59. Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Langner J, Schramm G, et al. PET/MRI in head and neck cancer: initial experience. Eur J Nucl Med Mol Imaging 2013; 40:6-11.